HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed) | PAR 24 197

Opportunity Information: Apply for PAR 24 197

The HEAL Initiative Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (PAR-24-197) is an NIH R03 pilot grant opportunity aimed at jumpstarting exploratory research on pain-relevant drug targets that are considered part of the "understudied druggable proteome." The central goal is to help researchers generate early, decision-enabling evidence that specific lesser-characterized proteins could be viable, druggable targets for pain and pain management. Rather than funding late-stage development or large-scale programs, this NOFO is structured to support short, focused projects that create the kind of preliminary data and practical tools needed to de-risk a new target and justify future, larger applications.

This opportunity specifically supports early-stage biochemical and/or biological research that advances characterization of eligible proteins named in the NOFO. In practice, that can include building foundational knowledge about protein function in relevant pain pathways, validating target engagement strategies, developing assays or reagents, establishing initial links between the protein and pain phenotypes, or generating proof-of-concept data that the target is tractable from a drug discovery perspective. The emphasis is on feasible pilot work that moves an understudied protein from "interesting but unknown" toward "actionable target" by providing concrete experimental results or enabling resources.

The NOFO sits within the broader NIH Helping to End Addiction Long Term (HEAL) Initiative, which is intended to accelerate the development of new medications across the opioid addiction cycle. While this particular funding call focuses on pain targets (rather than directly on addiction interventions), the connection to HEAL reflects a policy and scientific priority: improving pain treatment options can reduce reliance on opioids and support safer, more effective clinical management of pain, which in turn can influence risks related to chronic opioid use, withdrawal, craving, relapse, and overdose. In other words, identifying new non-opioid or opioid-sparing pain targets is viewed as a key upstream strategy that complements HEALs broader objectives.

The award mechanism is an R03, and clinical trials are not allowed under this announcement. That means applications should stay within preclinical and basic-to-early translational activities that do not involve prospective assignment of human participants to interventions. The budget information provided indicates an award ceiling of $100,000, which reinforces the pilot nature of the program and the expectation that proposed work is tightly scoped, high-impact for its size, and focused on producing clear next-step outputs (data, assays, reagents, and/or validated hypotheses around specific eligible proteins).

Eligibility is broad across many U.S.-based organization types, including state, county, and local governments; public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. Additional categories explicitly included are institutions and organizations that often participate in federal research and community-engaged programs, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. At the same time, non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, are allowed, which generally means a U.S. applicant organization may include certain well-justified international elements in the work when permitted and appropriately structured.

Administratively, the opportunity is offered by the National Institutes of Health as a discretionary grant program with activity areas spanning health and related public service domains. The original closing date listed is July 16, 2026. Overall, this NOFO is best viewed as a targeted on-ramp for investigators who want to bring rigor and momentum to neglected but potentially important pain biology by producing the early evidence and enabling tools needed to unlock future target validation and therapeutic discovery efforts.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.279, 93.350, 93.846, 93.853, 93.865, 93.866.
• This funding opportunity was created on 2024-04-17.
• Applicants must submit their applications by 2026-07-16. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $100,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 24 197

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: